Rodent study indicates that the motor cortex becomes disconnected during episodes of involuntary and uncontrollable movements ...

The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa.

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Symptomatic drug therapy should be initiated when parkinsonian symptoms become bothersome to the patient. L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

Department of Chemistry, Chungnam National University, Daejeon 34134, Republic of Korea ...

NeuroQuiet is an advanced auditory support supplement that takes hearing experience to the next level. It strategically combines superior herbal ingredients in the right proportion to defy auditory ...